PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Announces Private Placement of Equity
Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has
View HTML
Toggle Summary Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019
Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH LA JOLLA, Calif. , April 8, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced
View HTML
Toggle Summary Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2018
View HTML
Toggle Summary Regulus Announces Transition of Research Leadership
LA JOLLA, Calif. , March 15, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright , Chief Research and Development
View HTML
Toggle Summary Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
LA JOLLA, Calif. , Jan. 7, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as a clinical candidate for the treatment of
View HTML
Toggle Summary Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
No Adverse or Other Significant Findings to Date Across All Dose Groups Tested Data Package to Be Submitted to FDA to Support Potential Resumption of Phase 1 Clinical Study LA JOLLA, Calif. , Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused
View HTML
Toggle Summary Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of
View HTML
Toggle Summary Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
$47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Regulus Announces Successful Restructuring of Sanofi Collaboration
Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has
View HTML
Toggle Summary Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from ATHENA, its global natural history of disease
View HTML